{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:57:21Z","timestamp":1790675841995,"version":"4.1.0"},"reference-count":52,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The role of primary prophylaxis (PP) with granulocyte colony-stimulating factor (G-CSF) for patients with metastatic pancreatic adenocarcinoma (MPA) treated with FOLFIRINOX is unknown. We aimed to compare the frequencies of grades 3 or 4 neutropenia (G3\/4N) and febrile neutropenia (FN) and survival outcomes according to the use of PP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective study. We included patients with pathologically confirmed MPA treated with FOLFIRINOX in first-line. Patients who received primary prophylaxis (PP group) were compared to patients who received secondary or no G-CSF (no-PP group). Overall survival (OS) and progression-free survival (PFS) were evaluated using the standard Cox proportional hazard model. To account for potential biases, we performed sensitivity analyses excluding patients who received secondary prophilaxis and treating G-CSF as a time-dependent covariate in extended Cox proportional hazard models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study population consisted of 123 patients. PP was used by 75 patients (61.0%). G3\/4\u00a0N occurred more frequently among patients without PP (10.7 vs 41.7%; P &lt; .001). There was no difference in the frequency of FN between groups (5.3 vs 8.3%; P = .710). In multivariate analysis, PP was associated with a trend toward improved OS (HR = .66; 95% confidence interval [95% CI] .41 - 1.07; P = .094). In the multivariate model excluding patients with secondary prophylaxis (HR = .54; 95% CI 0.32 - .91; P = .022) and in the time-dependent model (HR = .47; 95% CI 0.28 - .80; P = .005), PP was associated with statistically superior OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite the reduction in the frequency of G3\/4N, the risk of FN among patients treated with FOLFIRINOX without G-CSF is too low to justify its use in a routine basis. However, given the potential of G-CSF to improve survival in this setting, further studies are warranted to assess its role during treatment with FOLFIRINOX for patients with MPA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10732748221149543","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T12:50:52Z","timestamp":1672663852000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on the Outcomes of Patients With Metastatic Pancreatic Adenocarcinoma (MPA) During First-Line Treatment With FOLFIRINOX: A Single-Center Retrospective Analysis"],"prefix":"10.1177","volume":"30","author":[{"given":"Angelo Borsarelli","family":"Carvalho de Brito","sequence":"first","affiliation":[{"name":"Medical Oncology Department, AC Camargo Cancer Center, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel P","family":"Riechelmann","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, AC Camargo Cancer Center, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4702-116X","authenticated-orcid":false,"given":"Victor Hugo","family":"Fonseca de Jesus","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, AC Camargo Cancer Center, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,1,2]]},"reference":[{"key":"bibr1-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"bibr2-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4869"},{"issue":"4","key":"bibr3-10732748221149543","first-page":"18","volume":"13","author":"Patel L","year":"2014","journal-title":"Oncology Exchange"},{"key":"bibr4-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12501"},{"key":"bibr5-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.010"},{"key":"bibr6-10732748221149543","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v12.i2.182"},{"key":"bibr7-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26811-9"},{"key":"bibr8-10732748221149543","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.04.02"},{"key":"bibr9-10732748221149543","volume-title":"Hematopoietic Growth Factors","author":"National Comprehensive Cancer Network (NCCN)","year":"2022"},{"key":"bibr10-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw325"},{"key":"bibr11-10732748221149543","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113137"},{"key":"bibr12-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.411"},{"key":"bibr13-10732748221149543","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"bibr14-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir073"},{"key":"bibr15-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.07.011"},{"key":"bibr16-10732748221149543","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.02.12"},{"key":"bibr17-10732748221149543","volume-title":"Using Time Dependent Covariates and Time Dependent Coefficients in the Cox Model","author":"Therneau T","year":"2021"},{"key":"bibr18-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.45"},{"key":"bibr19-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-02001-y"},{"issue":"5","key":"bibr20-10732748221149543","first-page":"497","volume":"13","author":"Peddi PF","year":"2012","journal-title":"JOP: Journal of the pancreas"},{"key":"bibr21-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0361-2"},{"key":"bibr22-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31829e2006"},{"key":"bibr23-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.e15232"},{"key":"bibr24-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2014.09.005"},{"key":"bibr25-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1159\/000439171"},{"key":"bibr26-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.222"},{"key":"bibr27-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-018-0137-x"},{"key":"bibr28-10732748221149543","first-page":"1","volume":"18","author":"Kang J","year":"2018","journal-title":"Invest New Drugs"},{"key":"bibr29-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0784-z"},{"key":"bibr30-10732748221149543","doi-asserted-by":"publisher","DOI":"10.26790\/BJO20181447A197"},{"key":"bibr31-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy132"},{"key":"bibr32-10732748221149543","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10110454"},{"key":"bibr33-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-017-0028-5"},{"key":"bibr34-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"bibr35-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04051-x"},{"key":"bibr36-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx369.142"},{"key":"bibr37-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919874650"},{"key":"bibr38-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-020-00203-7"},{"issue":"3","key":"bibr39-10732748221149543","first-page":"39","volume":"55","author":"Brooks GA","year":"2021","journal-title":"J Clin Oncol"},{"key":"bibr40-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13883"},{"key":"bibr41-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.201700067"},{"key":"bibr42-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211029825"},{"key":"bibr43-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.6995"},{"key":"bibr44-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.5776"},{"key":"bibr45-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00986-1"},{"key":"bibr46-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4126"},{"key":"bibr47-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2020.1807250"},{"key":"bibr48-10732748221149543","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10110454"},{"key":"bibr49-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.01.024"},{"key":"bibr50-10732748221149543","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01295"},{"key":"bibr51-10732748221149543","volume-title":"Pharmaceuticals provides update on pivotal phase 3 clinical trial in patients with metastatic pancreatic cancer and interim analysis of pivotal phase 3 clinical trial in patients with relapsed or refractory acute myeloid leukemia","author":"Rafael G","year":"2021"},{"issue":"4","key":"bibr52-10732748221149543","first-page":"40","volume":"560","author":"Fu Q","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748221149543","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748221149543","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748221149543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:23:22Z","timestamp":1777386202000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748221149543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":52,"alternative-id":["10.1177\/10732748221149543"],"URL":"https:\/\/doi.org\/10.1177\/10732748221149543","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/10732748221149543\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748221149543\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748221149543\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748221149543\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748221149543\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748221149543\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748221149543\/v1\/review2","asserted-by":"object"}]},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"10732748221149543"}}